Securities Class Action Lawsuit Filed Against Replimune Group, Inc.

Strategic Insights -

A securities class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities of the company between November 22, 2024, and July 21, 2025, both dates inclusive. The lawsuit claims that the company's statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

The lawsuit alleges that the defendants recklessly overstated the prospects of the IGNYTE trial, which resulted in the U.S. Food and Drug Administration deeming the trial inadequate and not well-controlled. When the true details entered the market, the lawsuit claims that investors suffered damages.

Key Takeaways:

  • The lawsuit claims that Replimune Group, Inc. made materially false and/or misleading statements and/or failed to disclose that the company's statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.
  • The lawsuit alleges that the defendants recklessly overstated the prospects of the IGNYTE trial, which resulted in the U.S. Food and Drug Administration deeming the trial inadequate and not well-controlled.
  • The lawsuit claims that investors who purchased Replimune securities during the Class Period may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
  • To join the Replimune class action, investors can go to [www.rosenlegal.com](http://www.rosenlegal.com) or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [pkim@rosenlegal.com](mailto:pkim@rosenlegal.com) for information on the class action.
  • A class action lawsuit has already been filed, and the lead plaintiff must move the Court no later than September 22, 2025, for the opportunity to act as lead plaintiff.
  • The Rosen Law Firm, which filed the lawsuit, has a track record of success in leadership roles and has represented investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • The firm achieved the largest ever securities class action settlement against a Chinese Company at the time and has been ranked in the top 4 each year since 2013 in securities class action settlements.

Statistics:

  • The lawsuit claims that investors suffered damages when the true details of the IGNYTE trial entered the market.
  • The Replimune class action was filed on September 1, 2025, with the Rosen Law Firm serving as the lead counsel.
  • The lead plaintiff must move the Court no later than September 22, 2025, for the opportunity to act as lead plaintiff.
  • The Rosen Law Firm has a track record of success in leadership roles, with over $438 million in recoveries for investors in 2019 alone.

Sources:

  • GlobeNewswire. (2025, September 1). WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the "Class Period"), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
  • The Rosen Law Firm, P.A. (2025). Contact Information.
  • COMTEX_468473991/2010/2025-09-01T22:05:00